Cardiovascular Portfolio

For the past 20 years, strong emphasis has been placed on improving the survival rate and quality of life of people living with cardiovascular diseases. Despite great efforts, long-term mortality rates have not declined and often quality of life for these patients has barely improved.

Hyloris’s goal is to change this, by developing life-saving intravenous and liquid products. These innovations will improve hospital care and the daily lives of patients at home with critical cardiovascular indications including Atrial Fibrillation, Congestive Heart Failure and Coronary Heart Disease.

Atrial fibrillation (AFib) is the most common type of irregular heartbeat. Under normal circumstances, the heart contracts and relaxes, allowing for a regular heartbeat. In AFib, the abnormal (uncoordinated) firing of electrical impulses causes the atria (the top chambers of the heart) to beat irregularly (quiver). This prevents blood from being properly pumped out of the heart. Blood can then pool and form a clot, which may lead to a stroke, heart failure, or other heart-related complications.  

If a clot breaks off, it can enter the bloodstream and lodge in an artery that leads to the brain—this is when a stroke may occur. Even though untreated atrial fibrillation doubles the risk of heart-related death and is associated with a five-fold increased risk of stroke, many patients are unaware that AFib is a serious condition.

An estimated 6.1 million people in the US are living with AFib. 1.2 million new cases are diagnosed annually, and the number of US patients living with AFib is expected to increase to 12.1 million by 2030.

IV formulation of sotalol, a commonly used antiarrhythmic drug, allowing for a significantly shorter (required) hospital stay for therapy initiation.

IV formulation of the antiarrhythmic drug Dofetilide currently only available as an oral capsule.

Congestive Heart Failure (CHF) is a chronic, progressive condition that affects the pumping power of the heart muscle. The heart cannot pump enough blood to the body, and eventually, blood and other fluids may accumulate inside other organs and body parts, such as the lungs, abdomen, liver, legs and feet.

CHF symptoms include shortness of breath, fatigue, swollen legs and rapid heartbeat.

Nearly 5.8 million people in the US are currently living with CHF, and approximately 550,000 new cases are diagnosed each year. Half of these patients have an average life expectancy of less than five years. And of those with the most severe form of heart failure almost 90% are expected to die within one year, according to the Heart Failure Society of America.

IV formulation of metolazone (an existing diuretic) providing faster onset of treatment in patients requiring diuresis and solving possible poor absorption related issues of the oral formulation.

Coronary Heart Disease (CHD) involves the reduction of blood flow to the heart muscle due to a build-up of plaques and fatty deposits on the wall of the heart’s coronary arteries. The plaques can rupture and form a blood clot that blocks or reduces blood flow, which may lead to a heart attack. There are multiple types of CHD, including stable angina, unstable angina, myocardial infarction and sudden cardiac arrest.

Between 2011 and 2014, 16.5 million adults in the US were living with prevalent CHD. It’s estimated that 605,000 new heart attacks and 200,000 recurrent heart attacks occur in the US annually. CHD is the primary cause of death, responsible for more than 370,000 US deaths every year.

HY-CVS-073 are intravenously administered antiplatelet agents administered to patients suffering from Acute Coronary Syndrome.

IV formulation of an oral antiplatelet product, offering needed faster onset of action in patients suffering from Acute Coronary Syndrome.
BACK TO ALL PRODUCTS